灯盏花素治疗血管性痴呆的临床研究

Clinical Study of Breviscapine Treated the Patients with Vascular Dementia

目的观察灯盏花素治疗血管性痴呆（VD）的临床疗效和对生活质量的影响。、方法将2003年2月～2005年6月医院住院的68例血管性痴呆患者随机分灯盏花素组和对照纽各34例。治疗纽给予灯盏花素100mg，每日1次，静脉滴注，20d为1疗程，对照组给予胞二磷胆碱0．75g，每日1次，静脉滴注，共20d，2组其他治疗相同，治疗前后评价采用简易智能状态检查表（MMSE）、生活功能量表（ADL）、长谷川痴呆量表（HDS）、痴呆严重程度临床评定量表（wMS）及血液流变学的变化指标。结果治疗纽用药后的MMSE（22．57±3．13），ADL（24．48±8．76），HDS（23．48±2．92），WMS（71．23±18．57）及血液流变学指标较对照组MMSE（20．61±3．83），ADL（28．89±14．47），HDS（21．12±6。43），WMS（61．04±22．54）明显改善，差异有显著或极显著性意义（P〈0.05或P〈0．01）。结论灯盏花素可明显改善VD的智能状态、认知功能及提高生活质量。

Objective To observe the effect of Breviscapine treated the patients with vascular dementia. Methods Sixty-eight patients with treated vascular dementia were randomly divided into two groups. The Breviscapine groups of 34 patients was treated with Breviscapine 100mg iv drip qd for 20d, the control groups of 34 patients was treated with citicoline 750mg iv drip for 20d then their MMSE, ADL, HDS, WMS were evaluated and the hemorheologic indexes were measured in both groups before and after treatment respectively. Results In Breviscapine group the scores of MMSE ADL HDS WMS were （22.57 ± 3.13 ）, （ 24.43 ± 8.72 ）, （23.48 ± 2.92 ）, （ 71.23 ± 18.57 ） and in control group were （20.61 ±3.83）, （ 28.89 ± 14.47）, （ 21.12 ±6.43）, （ 61.04 ±22.54） respectively there were significant differences between the two groups（P 〈 0.05 or P 〈 0.01 ）. Conclusion The Breviscapine is benefit for functional recovery of the recognize in vascular dementia patients.